Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B‐Cell Lymphoma to R‐ CHOP Chemoimmunotherapy
International Journal of Laboratory Hematology · 2025
DOI: 10.1111/ijlh.14440 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2025. Verfasst von Yara Mohamed Ahmed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Long noncoding RNAs (lncRNAs) have emerged as key regulators of cancer; in addition, they have been identified as novel therapeutic targets and biomarkers for several cancers, including diffuse large B‐cell lymphoma (DLBCL).
Methods
A total of 75 DLBCL patients and 30 control subjects with active lymph nodes were enrolled into our study. The baseline expression levels of lncRNAs HOTAIR, MALAT1, and PANDA in paraffin‐embedded blocks of lymph nodes from DLBCL patients and controls were evaluated using reverse transcription quantitative real‐time PCR (RTqPCR) technique.
Results
The expression levels of HOTAIR and MALAT1 were increased while PANDA expression level was decreased in DLBCL patients when compared to controls and in R‐CHOP‐resistant patients when compared to responder ones. Also, HOTAIR, MALAT1, and PANDA baseline expression levels were significantly correlated with the different clinical parameters in this study. As diagnostic and prognostic tools, the results obtained from the ROC curve revealed that the PANDA baseline expression level was the best one as the diagnostic biomarker could differentiate DLBCL disease and the prognostic biomarker predicts R‐CHOP resistance.
Conclusion
In conclusion, the integrated approach reveals that lncRNAs HOTAIR and MALAT1 were upregulated, while lncRNA PANDA was downregulated in DLBCL patients compared with controls, and the three lncRNAs closely associated with clinical prognosis. This study warrants future studies in clinical trials for the treatment of R‐CHOP‐resistant DLBCL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.
- Clinical Pathology-Hematology Department and Ain Shams Medical Research Institute, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Riham Abdel-Hamid Haroun
Zitieren
APA
Ahmed, Y. M., El-Khazragy, N., Haroun, R. A., & Fathy, S. A. (2025). Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B‐Cell Lymphoma to R‐ CHOP Chemoimmunotherapy. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14440
Vancouver
Ahmed YM, El-Khazragy N, Haroun RA, Fathy SA. Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B‐Cell Lymphoma to R‐ CHOP Chemoimmunotherapy. International Journal of Laboratory Hematology. 2025. doi:10.1111/ijlh.14440
BibTeX
@article{Ahmed2025,
author = {Ahmed, Yara Mohamed and El-Khazragy, Nashwa and Haroun, Riham Abdel-Hamid and Fathy, Shadia Abdel-Hamid},
title = {Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B‐Cell Lymphoma to R‐ CHOP Chemoimmunotherapy},
journal = {International Journal of Laboratory Hematology},
year = {2025},
doi = {10.1111/ijlh.14440}
}
EUVIMED